NMD4C Hire Research Software Developer
New Research Software Developer
The NMD4C are pleased to announce the hiring of research software developer Kevin LaFleur to the network’s biobanking team! Kevin holds a bachelor’s degree in music and cognitive science from McGill University and brings experience from technical and research assistant roles at labs and research groups in Montreal and Boston, most recently at Tore Nielsen’s Dream and Nightmare Lab at UdeM.
Role of the Developer
As a research software developer for the NMD4C and the Montreal Neurological Institute, Kevin works with Dr. Jason Karamchandani to develop the technical infrastructure for a centralized Canadian neuromuscular biobanking catalogue. Kevin works to link biospecimen, imaging and genetic information from neuromuscular biobanks across Canada to a central repository within the Neuro’s C-BIG project.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.